Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafenoquine dose-ranging post-exposure prophylaxis study for Plasmodium vivax malaria
ACTRN12607000588493Phase 3Completed
- Sponsor
- GSK
- Start
- Feb 1999
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of tafenoquine and primaquine in malaria (4 arms), sponsored by GSK. Primary endpoint: Proportion of subjects with confirmed parasitemia. Started Feb 1999; status: completed.
02
Drugs
tafenoquineprimaquine
03
Conditions
malaria
Beyond the preview
Go deeper on ACTRN12607000588493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000588493.